导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 7.45% | 884/4773 |
| 近一周 | -1.67% | 638/5462 |
| 近一月 | -1.67% | 996/5421 |
| 近一季 | -3.13% | 1352/5209 |
| 近半年 | 3.97% | 856/4920 |
| 近一年 | 11.68% | 897/4366 |
| 近两年 | 55.56% | 1322/2954 |
| 近三年 | 43.24% | 652/2253 |
| 成立以来 | 70.00% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.74% 1932/4961 |
13.90% 1920/5312 |
- - |
- - |
| 2025 | 22.13% 1996/4813 |
0.22% 1941/3635 |
3.40% 1017/4076 |
16.59% 2632/4524 |
1.09% 1545/4813 |
| 2024 | 17.17% 722/3463 |
5.99% 322/2808 |
1.17% 492/3014 |
11.94% 2442/3129 |
-2.37% 2060/3463 |
| 2023 | -10.17% 1272/2656 |
2.81% 1297/2280 |
-3.43% 795/2385 |
-3.24% 877/2515 |
-6.48% 1797/2655 |
| 2022 | -13.42% 329/2207 |
-9.34% 321/1919 |
9.03% 303/2016 |
-11.90% 607/2113 |
-0.58% 1626/2208 |
| 2021 | 3.47% 608/1822 |
-0.08% 329/1255 |
9.90% 513/1330 |
-5.19% 784/1466 |
-0.62% 1257/1822 |
| 2020 | 37.53% 380/1250 |
-9.46% 678/1028 |
18.41% 337/1067 |
13.75% 310/1164 |
12.78% 436/1184 |
| 2019 | 27.92% 527/1092 |
23.25% 561/739 |
-1.28% 296/788 |
0.20% 547/850 |
4.92% 767/918 |
| 2018 | - - |
- - |
- - |
-1.85% 266/660 |
-10.52% 203/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 鹏华沪深300指数增强A VS. 长安沪深300非周期A(740101) |